![Jonathan Leslie Tobin](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jonathan Leslie Tobin
Director/Board Member at Artios Pharma Ltd.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Robert Lyne | M | 41 | 7 years | |
Martin Roelsgaard Jakobsen | M | - |
STipe Therapeutics ApS
![]() STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | 5 years |
Neil Miller | M | - |
NRG Therapeutics Ltd.
![]() NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018. | 6 years |
Niall M. B. Martin | M | - |
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | 8 years |
Andrew Muncey | M | - |
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | 8 years |
Richard Rutter | M | - |
NRG Therapeutics Ltd.
![]() NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018. | - |
Christian Schetter | M | 60 |
STipe Therapeutics ApS
![]() STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | 5 years |
Paul Jackson | M | - |
Pheon Therapeutics Ltd.
![]() Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | - |
Arthur Roach | M | - |
NRG Therapeutics Ltd.
![]() NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018. | - |
Katherine Jackman | F | - |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | 8 years |
Paul Jackson | M | - |
Pheon Therapeutics Ltd.
![]() Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | 9 years |
Claus Elsborg Olesen | M | 50 |
STipe Therapeutics ApS
![]() STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | 6 years |
David Thurston | M | 69 |
Pheon Therapeutics Ltd.
![]() Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | 19 years |
Chris Nave | M | 49 |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | 17 years |
Helga Mikkelsen | M | - |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | 6 years |
Shaun A. Kirkpatrick | M | - |
Pheon Therapeutics Ltd.
![]() Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | 9 years |
Jonathan R. Savidge | M | - |
NRG Therapeutics Ltd.
![]() NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018. | 1 years |
Jess Smith | F | - |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | 5 years |
Bob Soh | M | - |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | 8 years |
Christopher Smith | M | - |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | 12 years |
Mara Macdonald | F | - |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | 5 years |
Pierre Legault | M | 63 |
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | 6 years |
Nora Brennan | F | 55 |
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | 3 years |
Phil Masterson | M | - |
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | - |
Thomas Mccarthy | M | - |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | 9 years |
Julie Cherrington | M | 66 |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | - |
Morten Graugaard Døssing | M | - |
STipe Therapeutics ApS
![]() STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | - |
Alan Naylor | M | - |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | 9 years |
Melissa Byrne | F | - |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | 6 years |
Roger Rooswinkel | M | 40 |
Pheon Therapeutics Ltd.
![]() Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | - |
Francesco Draetta | M | 39 |
NRG Therapeutics Ltd.
![]() NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018. | 2 years |
Serena Nik-Zainal | F | - |
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | - |
Prashanth Rajan | M | - |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | 3 years |
Amy Perkin | F | - |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | 4 years |
Elliott Dunn | M | - |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | 4 years |
Christina Kulis | F | - |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | 3 years |
Johann Bono | M | - |
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | - |
Jonathan Ledermann | M | - |
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | - |
Geoff Shapiro | M | - |
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | - |
Kate Groombridge | F | - |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | - |
Robin Carr | M | - |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | 3 years |
Rana Ali | F | - |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | 3 years |
Michael Carter | M | 86 |
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | - |
Katharine Giles | M | - |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | 12 years |
Michelle Doig | F | 50 |
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | 3 years |
Roberto Solari | M | - |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | 17 years |
Raphaël Wisniewski | M | 54 |
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | - |
Cyrus Mozayeni | M | 49 |
Pheon Therapeutics Ltd.
![]() Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | 1 years |
David Fisher | M | - |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | 18 years |
Stephen Thompson | M | - |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | 17 years |
Hamish Alan Cameron | M | 70 |
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | - |
Christopher Alan Keightley | M | 70 |
Pheon Therapeutics Ltd.
![]() Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | - |
John Hagan Pryce Bayley | M | - |
University of Oxford
| 21 years |
René Kuijten | M | 60 |
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | - |
Robert Daniels | M | - |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | 3 years |
Melissa McBurnie | M | - |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | 16 years |
Harry Finch | M | - |
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | - |
Ingmar Wahlqvist | M | - |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | 15 years |
Chen-Ming Yu | M | 50 |
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | - |
Regina Hodits | M | 53 |
STipe Therapeutics ApS
![]() STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | - |
Sten Verland | M | 67 |
STipe Therapeutics ApS
![]() STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | - |
Rajesh Chopra | M | 63 |
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | 5 years |
Jeffrey Albers | M | 52 |
Pheon Therapeutics Ltd.
![]() Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | - |
Michael Gladstone | M | 37 |
Pheon Therapeutics Ltd.
![]() Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | - |
Goslik Schepers | M | - |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | 6 years |
Michael Bettess | M | - |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | 8 years |
Richard Bethell | M | 61 |
STipe Therapeutics ApS
![]() STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | - |
Barbara Dalton | M | 69 |
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | - |
Grant Hawthorne | M | - |
NRG Therapeutics Ltd.
![]() NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018. | - |
Samantha Truex | F | - |
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | 2 years |
Claudio Nessi | M | 56 |
NRG Therapeutics Ltd.
![]() NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018. | - |
Natalie Sacks | M | 59 |
STipe Therapeutics ApS
![]() STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | 4 years |
Duncan Mackintosh | M | - |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | 8 years |
J. Read | M | 73 |
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
David C. U'Prichard | M | 75 | - | |
Truman Packard | M | - |
University of Oxford
| 7 years |
emma chandra | F | - |
University of Oxford
| 3 years |
Michael Devereux | M | - |
Imperial College London
University College London
| 4 years |
Chad Frischmann | M | - |
University of Oxford
| 5 years |
Wassim Matar | M | - |
University College London
| 4 years |
Simon Wolfgang Hartmut Goeller | M | 44 |
University of Oxford
| 5 years |
Alex Hood | M | - |
University of Oxford
| 4 years |
Tomasz George | M | 40 |
University College London
Imperial College London
| 6 years |
Guan Hua Liu | M | 41 |
Imperial College London
| 4 years |
Joshua Lowe | M | - |
Imperial College London
| 4 years |
Marcus Karia | M | - | - | |
denise xifara | M | - |
University of Oxford
| 9 years |
John Banham | M | 83 | - | |
Charlotte Parry | F | - | 5 years | |
Hong Jun Zhong | M | 53 |
University of Oxford
| 3 years |
Kai Yu Liu | M | 39 |
University of Oxford
| 4 years |
Catherine Fraser | F | - |
University of Oxford
| 4 years |
Akhil Paul | M | 39 |
University of Oxford
| 4 years |
Gao Meng | F | 43 |
University of Oxford
| 5 years |
Philip Hodges | M | - |
University of Oxford
| 7 years |
David John Rawlins | M | 43 |
University of Oxford
| 3 years |
John Matthew Patrick Hutton | M | 69 | - | |
Naseem Amin | M | 62 | 2 years | |
Giles Kerr | M | 65 |
University of Oxford
| 16 years |
Sam Blake | M | - |
University of Oxford
| 5 years |
Statistics
Country | Connections | % of total |
---|---|---|
United Kingdom | 93 | 93.00% |
Denmark | 8 | 8.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jonathan Leslie Tobin
- Personal Network